Composition of Australian influenza vaccine for the 2002 season

This report published in Communicable Diseases Intelligence Volume 26, No 1, March 2002 contains the WHO recommendations on the composition of influenza vaccines for 2002 Southern Hemisphere Season

Page last updated: 19 March 2002

A print friendly PDF version is available from this Communicable Diseases Intelligence issue's table of contents.


In order to select virus strains for the manufacture of Influenza Vaccine for 2002 Season, a meeting of the Australian Influenza Vaccine Committee (AIVC) on Influenza Vaccines was convened on 11 October 2001.

Having considered the information on international surveillance by WHO and up-to-date epidemiology and strain characterisation presented at the meeting, the Committee considered that the WHO recommendations on the composition of vaccines for 2002 Southern Hemisphere Season should be followed:

H1N1 strain: an A/New Caledonia/20/99 (H1N1)-like strain
A/New Caledonia/20/99 (IVR-116) is recommended as a suitable vaccine strain.
15 µg HA per dose.
H3N2 strain: an A/Moscow/10/99 (H3N2)-like strain
A/Panama/2007/99 (RESVIR-17) is recommended as a suitable vaccine strain.
15 µg HA per dose.
B Strain: A B/Sichuan/379/99-like strain
B/Johannesburg/5/99, B/Victoria/504/00 or B/Guangdong/120/2000 are recommended as the suitable vaccine strain.
15 µg HA per dose.


The SRID reagents for testing the potency of influenza vaccines for A/New Caledonia/20/99 (IVR-116) and A/Panama/2007/99 (RESVIR-17) are available from NIBSC and CBER/FDA.


This article was published in Communicable Diseases Intelligence Volume 26, No 1, March 2002

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now

This issue - Vol 26, No 1, March 2002